Simon Livesey

VoltVision digitises high and medium voltage industrial power networks, transforming raw power data into actionable information – improving operational efficiency and lowering emissions​. VoltVision helps companies in heavy industry such as mining reduce power costs, reduce downtime, reduce CO2 emissions and improve ESG reporting. Its unique ‘Plug and Play data extraction gateway (V-CUBE) and cloud-based AI platform (ViViD) provide near real-time automated analysis and visualisation dashboards. This means management and operations teams can continuously monitor their critical electrical assets and power networks, from anywhere in the world, giving them increased visibility and control. VoltVision’s solutions are no CAPEX, ‘quick-win’, low-cost and deliver fast return on investment (typically three months).

Celex is a leading biotechnology company focused on the research and development of cutting-edge cancer treatments. Our team of experienced scientists and physicians are dedicated to improving the lives of those affected by cancer through the discovery and development of innovative therapeutics. Utilising cutting-edge technology, developed by Professor Djamgoz over the course of 20 years of research, and a deep understanding of the underlying biology of cancer, we strive to bring new and effective treatment options to patients in need. Celex Oncology is committed to advancing the fight against cancer and improving the lives of those affected by this disease. Get in touch with the team today to learn more about our revolutionary therapeutics. Celex Oncology are currently raising capital to advance our research and make invasive tumours benign. Contact us to learn more!

Our aim is to put education at the forefront of talent engagement and acquisition. Education delivered by enterprise that’s free, accessible and entirely relevant to the skills needed in our rapidly changing world. We want people to be able to learn these skills – whoever they are, wherever they are and whenever they like. We’re changing the way the world engages, recruits and develops talent. Educate apprentices, graduates and professionals the skills needed for your business, with on-demand video training, powerful learning tools and data analytics. Join us!

Collagerie is your shortcut to style. Expertly curating the best of fashion, interiors, beauty and lifestyle. We celebrate shopping at every price point, bringing you an innovative way to discover things you’ll love. We will delight and inspire, finding you the one thing over everything.

Back pain is debilitating and limiting. It forces changes to the way people live and affects their quality of lie. Gelmetix addresses the most common cause of this critical problem through an efficient, cost effective and drug-free approach to preventing pain and restoring functionality and movement. Our patented polymer gel helps to restore the natural integrity of the disc itself. Injected directly, it rehydrates and stabilises, bringing back load-bearing properties and restoring the movement of the patient. Our polymer gel technology also has the potential to be adapted and extended for other uses. Gelmetix was founded in 2012, as a spin-off from the University of Manchester. In December 2020, Gelmetix was named “one of the most promising biotech start-ups in Europe” by EIT Health Catapult.

Chronic wounds affect ~100m people around the world, impacting quality of life & placing a huge burden on health systems. Despite the many innovations in wound care over the years, chronic wound healing rates have barely improved. Change is needed – patients, practitioners, and regulators across the industry are in urgent need of high-impact innovations in chronic wound care. SolasCure is at the forefront of addressing this demand, aiming to shift the current treatment paradigm with a high impact therapeutic approach to debridement, with the goal of enabling dramatic improvements in healing rates and patients’ quality of life. Aurase Wound Gel aims to address the huge unmet need for easy & effective debridement to return wounds to healing. It combines the enzyme Tarumase with hydrogel to debride wounds, reduce biofilm & promote healing. Tarumase is a highly-specific fibrinolytic enzyme cloned from maggot saliva, perfectly optimised by evolution for wound bed preparation. After successful Phase IIa trials, SolasCure is preparing for the next phase of clinical development to bring Aurase Wound Gel one step closer to improving the lives of millions of patients suffering from chronic wounds. For more information, you can find our peer-reviewed publications here: Clinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14805 Preclinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14079 The importance of our innovative technology has been widely recognised: - Innovate UK Global Incubator Programme (Innovate UK, the UK’s Innovation Agency), Texas Medical Center, 2024 - Biomedical Catalyst Grant (Innovate UK, the UK’s Innovation Agency), 2024 - EIC Accelerator Grant (European Innovation Council), 2023 - Life Sciences Innovator (UK Department for Trade and Business), 2023 - EIT Health Catapult, Biotech Category (European Institute of Innovation & Technology), 2022 - Winner 2019 URGO Mentorship Programme. Visit us at www.solascure.com

Zumper is the largest privately owned rental platform in North America with more than 178 million site visits a year. We’re proud to have been named a 2021 Best Startup Employer by Forbes and a 2021 Best Place to Work/Company with the Best Benefits by BuiltIn SF. We believe finding your new apartment is more than just a move. It’s something bigger. A step forward. A new beginning. A fresh start. Whether you’re moving across the country or across the street, you deserve to love where you land. Zumper is on a mission to change the way you rent forever, where renting a home is as easy as booking a hotel. By making this vision a reality, we’re creating the opportunity for everyone to live better from one fresh start to the next. To date, we’ve raised over $178 million from Kleiner Perkins, Goodwater Capital, Headline, Dawn Capital, and the Blackstone Group.

Empirical Ventures leads pre-seed and seed rounds for deep science startups that are creating century-defining technologies 🚀

VoltVision digitises high and medium voltage industrial power networks, transforming raw power data into actionable information – improving operational efficiency and lowering emissions​. VoltVision helps companies in heavy industry such as mining reduce power costs, reduce downtime, reduce CO2 emissions and improve ESG reporting. Its unique ‘Plug and Play data extraction gateway (V-CUBE) and cloud-based AI platform (ViViD) provide near real-time automated analysis and visualisation dashboards. This means management and operations teams can continuously monitor their critical electrical assets and power networks, from anywhere in the world, giving them increased visibility and control. VoltVision’s solutions are no CAPEX, ‘quick-win’, low-cost and deliver fast return on investment (typically three months).

Celex is a leading biotechnology company focused on the research and development of cutting-edge cancer treatments. Our team of experienced scientists and physicians are dedicated to improving the lives of those affected by cancer through the discovery and development of innovative therapeutics. Utilising cutting-edge technology, developed by Professor Djamgoz over the course of 20 years of research, and a deep understanding of the underlying biology of cancer, we strive to bring new and effective treatment options to patients in need. Celex Oncology is committed to advancing the fight against cancer and improving the lives of those affected by this disease. Get in touch with the team today to learn more about our revolutionary therapeutics. Celex Oncology are currently raising capital to advance our research and make invasive tumours benign. Contact us to learn more!

Our aim is to put education at the forefront of talent engagement and acquisition. Education delivered by enterprise that’s free, accessible and entirely relevant to the skills needed in our rapidly changing world. We want people to be able to learn these skills – whoever they are, wherever they are and whenever they like. We’re changing the way the world engages, recruits and develops talent. Educate apprentices, graduates and professionals the skills needed for your business, with on-demand video training, powerful learning tools and data analytics. Join us!